S&PAA and TAC convene cross sector leaders April 23 in DC to shape founding principles for a National Mental Illness Justice Center.
A novel, non-hallucinogenic, experimental drug shows statistically significant, rapid, and durable improvement in PTSD symptom severity in a phase 2 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results